Phaseline

Targets › PRPF31

PRPF31 (U4/U6 small nuclear ribonucleoprotein Prp31): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Mar 2028.

Involved in pre-mRNA splicing as component of the spliceosome. Required for the assembly of the U4/U5/U6 tri-snRNP complex, one of the building blocks of the spliceosome. (UniProt, Q8WWY3)

Open in Phaseline: the race on PRPF31, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PYC TherapeuticsVP-001
Oligonucleotide-peptide conjugate targeting PRPF31 mutation
PRPF31Phase 1Retinitis Pigmentosa 11Mar 2028

Conditions

Retinitis Pigmentosa 11 (1)

Modalities

small molecule (1)

Companies

PYC Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.